Serum Metabolomics Analysis of the Anti-Inflammatory Effects of Gallic Acid on Rats With Acute Inflammation

Yue Wu1,2†, Kuangyu Li2,3†, Maolin Zeng1, Boyang Qiao1 and Benhong Zhou1,2*

1Department of Pharmacy, Renmin Hospital of Wuhan University, Wuha, China, 2School of Pharmaceutical Sciences, Wuhan University, Wuhan, China, 3Hubei No. 3 People’s Hospital of Jianghan University, Wuhan, China

Background: Gallic acid (GA) is a natural small-molecule polyphenol having a wide range of pharmacological activities. Until now, some works have studied the effect and the mechanisms of GA against inflammation. However, whether or how gallic acid regulates the downstream metabolic disorder against acute inflammation remains unclear. The present study explored the protective effect and the potential mechanism of GA on acute inflammation through the metabolomics approach.

Methods: An acute inflammation rat model was induced by local injection of carrageenin. Local swelling on paw and serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) were assessed in Control, Model and Gallic acid groups, respectively. Serum metabolomics based on high-performance liquid chromatography coupled with mass spectrometry (HPLC-MS) was also established to collect rats’ metabolic profiles and explore the metabolic changes related to GA pretreatment.

Results: Compared to the Modal group, local pain, redness, and swelling induced by carrageenin were significantly alleviated in GA groups in addition to the dose-dependent decreases of TNF-α and IL-6. Metabolomics analysis found significant alterations in metabolic signatures between the carrageenin-induced inflammation and control groups. Twelve potential biomarkers were further identified in acute inflammation by principal component analysis (PCA) and partial least squares discrimination analysis (PLS-DA). In addition, when rats were pretreated with gallic acid, serum levels of eleven biomarkers were observed to restore partially. Metabolic pathway and networks analysis revealed that GA might invert the pathological process of acute inflammation by regulating the key biomarkers involved in linoleic acid metabolism, ascorbate and aldarate metabolism, pentose and glucuronate interconversions, and arachidonic acid (AA) metabolism pathways.

Conclusion: The study elucidates the protective effect of gallic acid against acute inflammation and its possible regulating mechanism from a metabolomic perspective. These results could provide a theoretical basis for clarifying gallic acid’s mechanism and potential medicinal value in curing inflammation disorder in the clinic.

Keywords: gallic acid, acute inflammation, metabolomics, protective effect, anti-inflammatory
INTRODUCTION

Inflammation is a common pathological phenomenon that plays a vital role in the human and animal disease spectrum. Excessive or inappropriate inflammatory responses are the basis of a series of pathological damage (Calder, 2006), resulting in various diseases, such as diabetes, atherosclerosis, rheumatoid arthritis, and some other life-threatening diseases (Pereira et al., 2011). In order to cure or prevent such diseases, anti-inflammatory regulation is now widely recognized and studied. The anti-inflammatory activities of natural ingredients are becoming increasingly attractive due to their relatively good safety properties and wide variety in nature.

Gallic acid is a well-known small-molecule polyphenol as the main component widespread in natural herbs such as pomegranate peel, Chinese gall, raspberry, and Radix Paeoniae Rubra (Zhang et al., 2018). As a natural antioxidant, gallic acid has a wide range of pharmacological activities, including antioxidant (Lambert and Elias, 2010), anti-inflammatory (Yoon et al., 2013; Seo et al., 2016), cardiovascular protection (Priscilla and Prince, 2009; Jia et al., 2018), bacteriostasis (Borges et al., 2013), hepatoprotection (Rasoel et al., 2010; Hsieh et al., 2014) and anti-tumor activity (Nam et al., 2016; Pang et al., 2017). In vitro, several studies have certified the therapeutic effects of gallic acid on inflammatory diseases. Shin et al. and Kim et al. reported the activity of gallic acid in restraining the LPS-induced NO, PEG-2, and the production of interleukin-6 (IL-6) but with no cytotoxicity (Seo et al., 2016; BenSaad et al., 2017). Sripandikulchai et al. studied the anti-inflammatory activity of the extract of the Phyllanthus emblica Linn. As the main component, gallic acid was able to inhibit the pro-inflammatory gene expression of cyclooxygenase-2 (COX-2), iNOS, IL-16, and IL-6 in a dose-dependent way (Sripandikulchai and Junlatat, 2014). In addition, Mishra et al. reviewed gallic acid’s effect in inhibiting the activation NF-kappaB(NF-kB) and protein kinase B (Akt) signaling pathways along with the activity of some enzymes, such as cyclooxygenase, ribonucleotide reductase, thus preventing the occurrence of inflammatory tumors in vitro (Verma et al., 2013). In vivo, the protective effect of gallic acid on inflammatory damages has also been revealed in some diseases or disorders, like obesity (Tanaka et al., 2020; Gwon and Yun, 2021), chronic obstructive pulmonary disease (Singla et al., 2021), diabetes (Rahimifard et al., 2020), cisplatin nephrotoxicity (Dehghani et al., 2020), neuroinflammatory (Liu et al., 2020), colitis (Pandurangan et al., 2015; Zhu et al., 2019), and infection (Reyes et al., 2018). The main mechanisms include lowering the expression of inflammatory mediators (Reyes et al., 2018; Zhu et al., 2019; Tanaka et al., 2020; Singla et al., 2021), suppressing the phosphorylation or the metastasis of p65-NF-kB (Pandurangan et al., 2015; Zhu et al., 2019; Singla et al., 2021), inhibiting the activation of the signal transcription and transduction factor (Pandurangan et al., 2015), and downregulating mRNA and protein expression (Liu et al., 2020; Singla et al., 2021).

Although gallic acid’s activity against inflammatory diseases has been studied in vitro and in vivo, most of the works have focused on gene and protein expression mechanisms. Whether or how gallic acid regulates the downstream metabolic disorder in inflammation is unclear. At present, the relationship between inflammation and metabolic disorder attracts attention. Accumulating evidence indicates that metabolic disorders can trigger systemic inflammation, which in turn may play a role in pathophysiology or even aggravate the disease itself (Wang et al., 2015; Wenzl et al., 2021). Furthermore, recent studies also inspired that therapies targeting to restore metabolic homeostasis have the potential to treat inflammation damage (Zhuo et al., 2012; Lei et al., 2021). Therefore, studies focusing on the metabolic regulation of gallic acid may be valuable to explore the therapeutic effect and potential mechanisms of the candidate in the cure of inflammation disorder.

As one of the important branches of system biology (Fiehn et al., 2000), metabolomics is now a powerful technique to systematically characterize physiological and pathological changes of organisms (van der Gref et al., 2004). By studying the organisms’ changes of metabolic profile in vivo and exploring the relationship between metabolites and the physiological and pathological states, metabolomics has shown highly effective in investigating the physiological status of the body, diagnosing diseases, identifying perturbed pathways, as well as revealing the therapeutic effects, the material bases, and the mechanism of action of drugs (Huo et al., 2014; Wang et al., 2018). In this study, we explored the anti-inflammatory effect of gallic acid on acute inflammation through the serum biochemistry analysis and metabolomics approach, to revealing the therapeutic effects, the material bases, and the mechanism of action of drugs. LC-MS analysis was performed to study the serum metabolic profiles of rats with acute inflammation induced by carrageenan. The principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) were conducted to investigate the changes of endogenous metabolites in order to evaluate the intervention effect of the gallic acid on inflammation. By identifying potential metabolic markers and analyzing metabolic pathways, the metabolic regulation of gallic acid was analyzed and discussed to provide insight into the systemic therapeutic effect of gallic acid on inflammation in vivo.

MATERIALS AND METHODS

Materials

Gallic acid, aspirin, and carrageenin were purchased from Aladdin Chemistry Co., Ltd. (Shanghai, China) and Rhawn (Shanghai, China), respectively. The ELISA kits for the determination of TNF-α and IL-6 were obtained from Jiangsu Meimian industrial Co., Ltd. (Jiangsu, China). The Cleanert S C18 was obtained from Agela Technologies Co., Ltd. (Tianjin, China). The solvents used for LC-MS analysis were of chromatographic grade, and all other chemicals and solvents were of analytical grade.

Animals

Forty-eight healthy male Sprague-Dawley rats (180 ± 20 g) were commercially obtained from Hubei Center for Disease Control
and Preven tion (Certificate NO. SCXK 2015-0018). Temperature and humidity were set at 21 ± 2°C and 60%. A regular 12 h light/dark cycle was established. All the rats were fed a standard diet with free access to water. The research did not include any human subjects. All animal experiments were approved by the ethics committee of Wuhan University, Wuhan, China, and carried out according to the National Institutes of Health guide to care and use laboratory animals.

After acclimatization for 7 days, rats were randomly divided into six groups respectively containing eight rats, including normal control group (Control), acute inflammation Group (Model), high-dose gallic acid group (150 mg/kg, GAH), middle-dose gallic acid group (100 mg/kg, GAM), low-dose gallic acid group (50 mg/kg, GAL), and positive control group. Due to the effect of aspirin, a typical NSAID, against carrageenan-induced inflammation in previous reports, aspirin was selected as the control in positive control group (Aspirin) (Yao et al., 2015; Shui et al., 2016; Mahmoudi et al., 2021). The Control and Model groups were gavaged with 2 ml of normal saline for three consecutive days, and Aspirin group was gavaged with aspirin (20 mg/kg/day) (Ma et al., 2020). In GAH, GAM, GAL groups, rats were administrated with gallic acid (150, 100, and 50 mg/kg/day, respectively) in the same way (Wei et al., 2018). Acute inflammation was induced 0.5 h after gavage on the third day. Rats in the group of Model, GAH, GAM, GAL, and Aspirin were subcutaneously injected with 0.1 ml of 1.0% carrageenan in the sub-plantar region of the right hind paws and the corresponding volume was 10 uL. The mass spectrometer was operated in negative ionization mode. The MS spectra were acquired from m/z 50 to m/z 1,000.

**Data Analysis**

The data matrix, consisting of retention time and normalized peak area of metabolites, was imported into the SIMCA-P + 12.0 software (Umetrics, Sweden) and MetaboAnalyst 3.0 online software for multivariate data analysis, including pattern recognition based on PCA and PLS-DA. Potential biomarkers were selected according to the values of variable importance in the projections (VIP > 1) through PLS-DA and the peak areas of different metabolites were further compared by T-test using SPSS 19.0 software for verification.

The databases such as Human Metabolome Database (HMDB) (http://www.hmdb.ca) and KEGG (http://www.kegg.jp/) were used for biomarker identification. The pathway analysis of potential biomarkers was performed with Metabolomics pathway analysis (MetPA) webserver software to identify the affected metabolic pathway analysis and visualization.

**Statistical Analysis**

Pharmacodynamic data TNF-α and IL-6 levels were tested by one-way analysis of variance (ANOVA), and Student’s t-test tested differential metabolites levels. Data analysis was carried out by SPSS 19.0 software. The significant difference was considered at p < 0.05, and an extremely significant difference was considered at p < 0.01.

**RESULTS**

**Evaluation of the Anti-inflammatory**

The Model group rats’ paws were swelling and fever 2 hours after carrageenan injection, indicating that acute inflammation models were established successfully. Compared with the Model group, the paw swelling degree decreased in GA groups, indicating that gallic acid could ameliorate the paw swelling induced by carrageenan in the rat model.

TNF-α and IL-6 are two of the typical inflammatory factors that play a vital role in inflammation. The inhibition effects of different doses of gallic acid on serum TNF-α and IL-6 were evaluated, and the results were shown in Table 1; Figure 1. Compared with the Control group, the levels of TNF-α and IL-6
were highly significantly \((p < 0.01)\) increased in the Model group 2 h after carrageenan injection. It indicated that carrageenan-induced local inflammation stimulation triggered a systematic inflammatory response. Compared with the Model group, the serum TNF-α levels decreased highly-significantly \((p < 0.01)\) in the GAH, GAM, and GAL groups, indicating that gallic acid was very effective in reducing TNF-α in serum. All doses of gallic acid could also lead to the decrease of IL-6 in serum. A significant difference \((p < 0.05)\) was observed between Mode, GAL and GAM groups, and a highly significant difference \((p < 0.01)\) was shown between GAH and Aspirin groups. Considering that middle-dose gallic acid showed a nice inhibition effect on the level of TNF-α and IL-6, the middle-dose gallic acid was used further to explore the anti-inflammatory mechanism through the metabolomics approach.

**Multivariate Data Analysis**

HPLC-MS/MS was used to characterize the metabolic profiles of serum samples in negative ion mode. Twenty-eight metabolites were found, and changes of metabolites were shown in the heatmap in Figure 2. The unsupervised PCA analysis on the data of different groups was performed to visualize general clustering, trends, or outliers among the observations. The PCA results were displayed as score plots, which represented the distribution of samples. As shown in Figure 3A, the perfect separation of four groups was observed, indicating that each group had utterly different metabolic profiling. The most significant distance was found between the Control and Model group in PCA score plots, which reflected the perturbed metabolism in acute inflammatory and the successful establishment of the rat model. Plots of GA and Aspirin groups were situated between the Control and Model groups. It revealed that drug therapy could induce substantial and characteristic changes in metabolic profiles. In addition, like aspirin, a typical anti-inflammatory drug, pretreatment of gallic acid in rats changed metabolic profile from the state of disease to normal health, suggesting that gallic acid may ameliorate the physiological metabolism disorder of rats with acute inflammation.

**Identification and Analysis of Metabolites**

In addition to the PCA analysis, a PLS-DA model was also established to search and identify the characteristic metabolic biomarkers associated with the inflammatory disorder in rat models (Figures 3B, C). Compared to PCA, the PLS-DA model is a supervised analysis that can better distinguish the difference between groups. After optimization, The quality parameters of the PLS-DA model between Control and Model groups were: \(R^2X = 0.645, R^2Y = 0.997,\) and \(Q^2 = 0.94.\) Loading plots of PLS-DA were tested with 200 random permutations to assure reliability and guard against overfitting (Figure 3D).

Based on the VIP values \((VIP > 1)\) and correlation of Student’s \(t\)-test and \(p\) value \((p < 0.05)\) in PLS-DA, twelve metabolic biomarkers were identified by comparing the metabolic profiles of the Control group with the Model. The details of these potential biomarkers are provided in Table 2, Figure 4. Compared to the Model group, eight identified metabolic biomarkers were significantly reduced in the Model group, while the remaining four markers were increased correspondingly. In addition, when the rats were pretreated with gallic acid, eleven of these metabolites (except succinic acid) showed a significant tendency to be normal, suggesting that gallic acid may fight against the inflammatory damage by regulating the disturbed endogenous biomarkers.

**Metabolic Pathway Analysis**

In order to explore the potential mechanism and the regulatory network of the gallic acid’s anti-inflammation effect, twelve metabolic biomarkers were further analyzed through metabolic pathway analysis. The pathway enrichment analysis of endogenous differential metabolites was further performed by MetaboAnalyst 5.0. Seventeen metabolic pathways were found to
be associated with carrageenin-induced inflammation in rats (Figure 5A). Four pathways with an impact value > 0.1 were considered to have the strongest correlation with the carrageenin-induced inflammatory disorder. These four pathways involved linoleic acid metabolism (impact value = 1.0), ascorbate and aldarate metabolism (impact value = 0.25), arachidonic acid metabolism (0.33292), and pentose and glucuronate interconversions (impact value = 0.125) (Figure 5B; Table 3). By referring to the existing literature and online databases such as KEGG and HMDB, the metabolic networks were structured and shown in Figure 6.

**DISCUSSION**

Inflammation is an essential immune response that promotes the survival of a host in the presence of a variety of internal and external insults (Hunter et al., 2009). Nevertheless, excessive inflammation may destroy cells or disturb cellular metabolism, thus contributing to chronic diseases and even death. Anti-inflammatory regulation has become attractive in preventing or curing inflammation-associated disorders. Gallic acid is a well-known natural polyphenol with various pharmacological activities. Although some previous studies have demonstrated the mechanism of the anti-inflammation of gallic acid, its effect in regulating the metabolic disorder in inflammation is unclear. In this research, a metabolomics approach was applied to give a global view of the characteristic metabolic profile associated with the anti-inflammatory effect of gallic acid. It will provide insight into the systemic therapeutic effect of gallic acid in inflammation diseases and help elucidate its mechanisms of action.

A carrageenin-induced inflammation mice model was used to evaluate the effect of the anti-inflammation of gallic acid in the present study. Carrageenin is a polysaccharide vegetable gum obtained from Irish moss, which can induce a neutrophil-mediated acute inflammatory response when injected into the sub-plantar region of mice. This model is well-researched and highly reproducible, thus usually used to study acute inflammatory processes (Morris, 2003). In this research, after being injected with 0.1 ml of 1.0% carrageenan,
paw edema with redness and swelling and elevated serum TNF-α and IL-6 were observed in the Model group, indicating that the acute inflammation model was successfully established. While in GA groups, the paw edema was significantly alleviated with gallic acid administration. Decreased levels of inflammatory cytokines TNF-α and IL-6 were also observed in serum biochemistry analysis and were dose-dependent with gallic acid pretreatment. It demonstrated that the anti-inflammatory effect of gallic acid might be associated with the down-regulation of TNF-α and IL-6. These results were similar to the results reported by Tahereh et al. and Fan et al. (Setayesh et al., 2019; Zhu et al., 2019; Singla et al., 2020).

In the study of drug metabolomics, the isolation, purification, and identification of endogenous substances in biological samples are critical. Biological samples have the characteristics of complex components, low concentration of substances to be measured, and more interfering substances. Therefore, high sensitivity and high specificity analysis methods are required, and pretreatment such as separation and concentration is also undergone before the analysis. Solid-phase extraction (SPE) is an effective pretreatment technology that combines solid-liquid extraction and column liquid chromatography. Compared with traditional extraction, SPE can separate impurities more effectively, with shorter sample treat time and more convenient operation. In our study, C18 SPE was used to pretreat the serum samples, and the high-resolution

**TABLE 2 | Summary of potential metabolite markers.**

| No | Metabolites     | R.T. (min) | m/z     | Molecule Composition | VIP Value | Model   | GAM   |
|----|----------------|------------|---------|----------------------|-----------|---------|-------|
| 1  | Oleic acid     | 39.297     | 282.2559| C_{18}H_{34}O_{2}    | 1.496     | ↓**     | ↑##   |
| 2  | Malic acid     | 40.009     | 134.0215| C_{4}H_{6}O_{5}      | 1.483     | ↓**     | ↑##   |
| 3  | D-Glucuronic acid | 29.322   | 194.0426| C_{6}H_{12}O_{7}     | 1.478     | ↑**     | ↓##   |
| 4  | Hexadecanoic acid | 38.79   | 256.2402| C_{16}H_{32}O_{2}    | 1.458     | ↑**     | ↓##   |
| 5  | Stearic acid   | 42.386     | 284.2715| C_{18}H_{36}O_{2}    | 1.441     | ↑**     | ↓##   |
| 6  | Indole         | 4.629      | 117.0578| C_{8}H_{7}N         | 1.438     | ↑**     | ↓##   |
| 7  | (R)-3-Hydroxybutyric acid | 3.421 | 104.0473| C_{4}H_{8}O_{3}     | 1.389     | ↑**     | ↓##   |
| 8  | Isoleucine     | 6.482      | 131.0946| C_{6}H_{13}NO_{2}   | 1.361     | ↑**     | ↓##   |
| 9  | Linoleic acid  | 37.507     | 280.2402| C_{20}H_{32}O_{2}    | 1.319     | ↑**     | ↓##   |
| 10 | Kynurenic acid | 20.49      | 189.0426| C_{10}H_{7}NO_{3}   | 1.315     | ↑**     | ↓##   |
| 11 | Succinic acid  | 1.044      | 118.0266| C_{4}H_{6}O_{4}     | 1.186     | ↑**     | ↓##   |
| 12 | Arachidonic acid | 37.254  | 304.2402| C_{20}H_{32}O_{2}    | 1.178     | ↑**     | ↓     |

Compared with the Control group, *p < 0.05, **p < 0.01; Compared with the Model group, *p < 0.05, **p < 0.01.
Orbitrap MS was used to detect endogenous metabolites in serum samples.

As an overall framework, metabolomics characterizes the functional phenotype of a system under certain conditions through the low molecular weight metabolites. Through high-resolution analytical detection and multidimensional statistical analysis, metabolomics presents a global view of endogenous and exogenous metabolites to study the fundamental causes of diseases, drug toxicity or identify the biomarkers associated with the diagnosis or therapeutic efficacy. This study compared the serum metabolomics characteristics of normal rats and acute inflammation modeled rats using an HPLC-MS platform and multivariate data analysis. Compared with the control group, there was a significant metabolic disorder in the model group, indicating that local stimulation of carrageenan caused systemic inflammation in rats. Twelve relevant metabolites were then screened out by PCA and PLS-DA analysis, including oleic acid, malic acid, D-glucuronic acid, hexadecanoic acid, stearic acid, indole, 3r-hydroxy-butanoic acid, isoleucine, linoleic acid, canine urine, succinic acid, and arachidonic acid. In addition, when pretreatment of gallic acid was applied, eleven of these metabolites (except succinic acid) showed a significant tendency to be normal. These potential metabolites are mainly involved in linoleic acid metabolism, ascorbate and aldarate metabolism, pentose and glucuronate interconversions, and arachidonic acid metabolism. Most of the control group, there was a significant metabolic disorder in the model group, indicating that local stimulation of carrageenan caused systemic inflammation in rats. Twelve relevant metabolites were then screened out by PCA and PLS-DA analysis, including oleic acid, malic acid, D-glucuronic acid, hexadecanoic acid, stearic acid, indole, 3r-hydroxy-butanoic acid, isoleucine, linoleic acid, canine urine, succinic acid, and arachidonic acid. In addition, when pretreatment of gallic acid was applied, eleven of these metabolites (except succinic acid) showed a significant tendency to be normal. These potential metabolites are mainly involved in linoleic acid metabolism, ascorbate and aldarate metabolism, pentose and glucuronate interconversions, and arachidonic acid metabolism. Most of
these potential metabolites are directly or indirectly connected with each other.

In metabolic networks, lipid metabolism is closely related to inflammation (Kubala et al., 2010). Arachidonic acid (AA) is an essential fatty acid existing in the cell membrane in the form of phospholipids [29]. When the cells are under stress, especially in response to inflammatory stimulation, AA is released from the phospholipids and then oxidized or modified into various bioactive metabolites, including prostaglandins, thromboxanes, and leukotriene, thus promoting inflammatory cascades (Yao et al., 2015; Wang et al., 2019).

### TABLE 3 | Metabolic pathway enrichment table of rat serum.

| NO. | Pathway Name                                | Total cmpd | Hits | RawP         | Impact | Details |
|-----|---------------------------------------------|------------|------|--------------|--------|---------|
| 1   | Biosynthesis of unsaturated fatty acids     | 36         | 5    | 4.0831E-6    | 5.389  | 0.0     | KEGG    |
| 2   | Butanoate metabolism                        | 15         | 2    | 0.0057498    | 2.2403 | 0.0     | KEGG    |
| 3   | Synthesis and degradation of ketone bodies  | 5          | 1    | 0.039185     | 1.4089 | 1.0     | KEGG    |
| 4   | Linoleic acid metabolism                    | 5          | 1    | 0.039185     | 1.4089 | 0.0     | KEGG    |
| 5   | Valine, leucine and isoleucine biosynthesis | 8          | 1    | 0.062015     | 1.2075 | 0.0     | KEGG    |
| 6   | Ascorbate and aldolate metabolism           | 10         | 1    | 0.076958     | 1.1137 | 0.25    | KEGG    |
| 7   | Pentose and glucuronate interconversions     | 18         | 1    | 0.13457      | 0.87104| 0.125   | KEGG    |
| 8   | Citrate cycle (TCA cycle)                   | 20         | 1    | 0.14845      | 0.82841| 0.03273 | KEGG    |
| 9   | Propanoate metabolism                       | 23         | 1    | 0.16889      | 0.7724 | 0.0     | KEGG    |
| 10  | Alanine, aspartate and glutamate metabolism | 28         | 1    | 0.20195      | 0.69475| 0.0     | KEGG    |
| 11  | Inositol phosphate metabolism               | 30         | 1    | 0.21484      | 0.66789| 0.0     | KEGG    |
| 12  | Arachidonic acid metabolism                 | 36         | 1    | 0.25235      | 0.59799| 0.33292 | KEGG    |
| 13  | Fatty acid metabolism                       | 39         | 1    | 0.27049      | 0.56785| 0.0     | KEGG    |
| 14  | Fatty acid elongation                       | 29         | 1    | 0.27049      | 0.56785| 0.0     | KEGG    |
| 15  | Valine, leucine and isoleucine degradation  | 40         | 1    | 0.27645      | 0.55839| 0.0     | KEGG    |
| 16  | Fatty acid biosynthesis                     | 47         | 1    | 0.3169       | 0.49908| 0.01472 | KEGG    |
| 17  | Aminocacyl-tRNA biosynthesis                | 48         | 1    | 0.32251      | 0.49146| 0.0     | KEGG    |

**Partial Compound:** the total number of compounds in the pathway; **hits:** the matched number from the user uploaded data; **RawP:** the original p-value calculated from the enrichment analysis; **Impact:** pathway impact value calculated from pathway topology analysis.

### FIGURE 6 | Metabolic networks of potential biomarkers in rat serum. Note: Metabolites in red and blue represent levels increased and decreased in the Model group, respectively.
precursor linoleic acid, but only the biological transformed AA is pro-inflammatory (Monteiro et al., 2013). In the present work, the decrease of serum linoleic acid was observed in the Model group along with the increase of arachidonic acid. It is consistent with the conclusion that inflammatory stimuli trigger the transformation of AA in the acute inflammation process. Moreover, with the intervention of gallic acid, serum linoleic acid tended to increase with the corresponding decrease of arachidonic acid, suggesting that gallic acid might act as an anti-inflammatory by regulating the transformation of AA in vivo.

D-glucuronic acid is one of the potential metabolic biomarkers that has been identified in inflammation (Dong et al., 2021; Olsson et al., 2021). Elevated D-glucuronic acid was found in the zebrafish model to be against the inflammatory response (Dong et al., 2021). Plasma D-glucuronic acid has also been reported to help the discrimination of patients with inflammation (Olsson et al., 2021). D-Glucuronic acid is a metabolite of glucose in vivo. It is formed from glucose by the multi-step metabolic process including citrate cycle, propanoate metabolism, pentose and glucuronate interconversions, and further converted to ascorbic acid or xylulose in ascorbic acid metabolism through a sequence of enzyme-driven steps (Liu et al., 2015). Ascorbic acid, known as vitamin C, is an ingredient with well-known antioxidant, anti-inflammatory, and immunomodulatory activities (Kianian et al., 2019). Ascorbic acid can inhibit the activation of the leukocyte myeloperoxidase/H2O2/Halide system, thereby improving leukocyte movement (Yara et al., 2013). In this study, the level of D-glucuronic acid increased in the Model group compared with the Control group, which is consistent with the previous reports (Dong et al., 2021; Olsson et al., 2021). It suggested that the carrageenin stimulated the release of more ascorbic acid to suppress inflammation. When the gallic acid intervention was applied, the serum level of D-glucuronic acid decreased, indicating that the medication of gallic acid can fight against the inflammatory response in vivo.

Isoleucine, leucine, and valine are essential branched amino acids that serve as substrates and signaling molecules to regulate protein synthesis in skeletal muscle. Skeletal muscle produces most of the body’s glutamine, the substrate for cell proliferation, including immune cells. In our study, when inflammation occurs, isoleucine content decreases, which may be caused by the consumption of isoleucine resulting from the proliferation of extensive inflammatory cells. With the pretreatment of gallic acid, the level of isoleucine increased, which may be that gallic acid inhibits the proliferation of inflammatory cells. In addition, the tryptophan (TRP)-kynurenine (KYN) metabolic pathway is proposed to be an emerging player in immunoregulatory networks in vivo due to its importance in mediating the equilibrium between activation and inhibition of the immune system (Mándi and Vécsei, 2012). TRP-KYN pathway is the primary metabolic pathway of tryptophan that is significantly activated by acute and chronic immune responses. Over 95% of TRP was catalyzed and transformed into a variety of metabolites, including KYN, kynurenic acid (KYNA), xanthurenic acid (XA) and cinnabarinic acid (CA) (Tanaka et al., 2021). These metabolites subsequently play a key role in modulating inflammation through positive or negative feedback loops and in the induction of immune tolerance. In this study, the level of kynurenine acid increased in the Model group. It indicated that more tryptophan is metabolized to form kynurenine acid during inflammation. After the intervention of gallic acid, the level of kynurenine acid decreased. It suggested that ellagic acid may help to restore the immune balance by regulating kynurenine metabolism.

CONCLUSION

In the present work, we investigated the regulating effect of gallic acid on the downstream metabolic disorder in inflammation. A characteristic metabolic profile including 12 metabolic markers was identified in acute inflammation with HPLC-MS-based metabolomics and multivariate data analysis. These potential metabolites are mainly involved in linoleic acid metabolism, ascorbate and aldarate metabolism, pentose and glucuronate interconversions, and arachidonic acid metabolism pathways. The metabolic pathways analysis revealed that gallic acid could exert its anti-inflammatory effect by increasing antioxidant capacity, regulating lipid metabolism, alleviating the amplification of inflammatory cascades, inhibiting the proliferation of immune cells, and promoting the immune balance. These results could provide a theoretical basis for clarifying the mechanism of the anti-inflammatory effect of gallic acid.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by the Ethics Committee of Wuhan University.

AUTHOR CONTRIBUTIONS

BZ designed the manuscript. KL developed the study protocol, coordinated data collection. YW, KL, and BQ performed data analyses, reported study results, and drafted the manuscript. MZ searched the literature. All authors contributed to the article and approved the manuscript for publication.

FUNDING

The work was supported by the National Natural Science Foundation of China (Grant No. 31570349).
Singla, E., Dharwal, V., and Naura, A. S. (2021). Gallic Acid Protects against the COPD-Linked Lung Inflammation and Emphysema in Mice. Inflamm. Res. 69, 423–434. doi:10.1007/s00011-020-02133-1

Singla, E., Puri, G., Dharwal, V., and Naura, A. S. (2021). Gallic Acid Ameliorates COPD-Associated Exacerbation in Mice. Mol. Cel Biochem 476, 293–302. doi:10.1007/s11010-020-03905-5

Sripandikulchai, B., and Junlatat, J. (2014). Bioactivities of Alcohol Based Extracts of Phyllanthus Emblica Branches: Antioxidation, Antimalanogenesis and Anti-Inflammation. J. Nat. Med. 68, 615–622. doi:10.1007/s11418-014-0824-1

Tanaka, M., Sugama, A., Sumi, K., Shimizu, K., Kishimoto, Y., Kondo, K., et al. (2020). Gallic Acid Regulates Adipocyte Hypertrophy and Suppresses Inflammatory Gene Expression Induced by the Paracrine Interaction between Adipocytes and Macrophages In Vitro and In Vivo. Nutr. Res. 73, 58–66. doi:10.1016/j.nutres.2019.09.007

Tanaka, M., Toth, F., Polyak, H., Szabo, A., Mandi, Y., and Vecsei, L. (2021). Neutral Lipoxygenase 1 modulates the CNS inflammatory response to gastric irritants. Brain Behav. Immunol. 99, 140–148. doi:10.1016/j.bbi.2021.07.118

Wang, X., Hunter, D., Xu, J., and Ding, C. (2015). Metabolic Triggered Arachidonic Acid Metabolism and Kidney Inflammation. Int. J. Mol. Sci. 20 (15), 3683. doi:10.3390/ijms20153683

Wang, X., Hunter, D., Xu, J., and Ding, C. (2015). Metabolic Triggered Inflammation in Osteoarthritis. Osteoarthr. Cartil. 23, 22–30. doi:10.1016/j.joca.2014.10.002

Wei, G., Wu, Y., Gao, Q., Shen, C., Chen, Z., Wang, K., et al. (2018). Gallic Acid Attenuates Postoperative Intra-Abdominal Adhesion by Inhibiting Inflammatory Reaction in a Rat Model. Med. Sci. Monit. 24, 827–838. doi:10.12659/MSM.908550

Wenzl, F. A., Ambrosini, S., Mohammed, S. A., Kraer, S., Lüscher, T. F., Costantino, S., et al. (2021). Inflammation in Metabolic Cardiomyopathy. Front. Cardiovasc. Med. 8, 742178. doi:10.3389/fcmr.2021.742178

Yao, W., Zhang, L., Hua, Y., Ji, P., Li, P., Li, J., et al. (2015). The Investigation of Anti-Inflammatory Activity of Volatile Oil of Angelica Sinensis by Plasma Metabolomics Approach. Int. Immunopharmacol 29, 269–277. doi:10.1016/j.intimp.2015.11.006

Yara, S., Lavoie, J. C., Beaulie, J. F., Delvin, E., Amre, D., Marcil, V., et al. (2013). Iron-Ascorbate-Mediated Lipid Peroxidation Causes Epigenetic Changes in the Antioxidant Defense in Intestinal Epithelial Cells: Impact on Inflammation. PLoS One 8, e63456. doi:10.1371/journal.pone.0063456

Zhang, J., Li, X., Wei, J., Chen, H., Lu, Y., Li, L., et al. (2018). Gallic Acid Inhibits the Expression of Keratin 16 and Keratin 17 through Nrf2 in Psooriasis-Like Skin Disease. Int. Immunopharmacol 65, 84–95. doi:10.1016/j.intimp.2018.09.048

Zhu, L., Gu, P., and Shen, H. (2019). Gallic Acid Improved Inflammation via NF-κB Pathway in TNBS-Induced Ulcerative Colitis. Int. Immunopharmacol 67, 129–137. doi:10.1016/j.intimp.2018.11.049

Zhuo, Q., Yang, W., Chen, J., and Wang, Y. (2012). Metabolic Syndrome Meets Osteoarthritis. Nat. Rev. Rheumatol. 8, 729–737. doi:10.1038/nrrheum.2012.135

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wu, Li, Zeng, Qiao and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.